These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Westerink J; Visseren FL Eur J Clin Invest; 2010 Jan; 40(1):87. PubMed ID: 19912317 [No Abstract] [Full Text] [Related]
5. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Morita T; Morimoto S; Nakano C; Kubo R; Okuno Y; Seo M; Someya K; Nakahigashi M; Ueda H; Toyoda N; Kusabe M; Jo F; Takahashi N; Iwasaka T; Shiojima I Intern Med; 2014; 53(4):307-14. PubMed ID: 24531086 [TBL] [Abstract][Full Text] [Related]
6. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence. Mascitelli L; Pezzetta F; Goldstein MR Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735 [TBL] [Abstract][Full Text] [Related]
7. Role of ezetimibe in the management of patients with atherosclerosis. Hamilton P Coron Artery Dis; 2009 Mar; 20(2):169-74. PubMed ID: 19106797 [TBL] [Abstract][Full Text] [Related]
8. [Ezetimibe (Ezetrol) in patients with diabetes]. Scheen AJ; Radermecker RP Rev Med Liege; 2009 Dec; 64(12):606-11. PubMed ID: 20143743 [TBL] [Abstract][Full Text] [Related]
9. The Zetia challenge: an update. Johns Hopkins Med Lett Health After 50; 2009 Apr; 21(2):6. PubMed ID: 19489149 [No Abstract] [Full Text] [Related]
10. [The current debate on lowering LDL cholesterol with ezetimibe]. Erdmann E Dtsch Med Wochenschr; 2010 Sep; 135(36):1742. PubMed ID: 20812160 [No Abstract] [Full Text] [Related]
11. Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. Armitage J Heart; 2008 May; 94(5):643-5. PubMed ID: 18411355 [No Abstract] [Full Text] [Related]
12. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease. Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589 [No Abstract] [Full Text] [Related]
13. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Howard WJ Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890 [TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Ahmed MH; Byrne CD Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342 [TBL] [Abstract][Full Text] [Related]
15. Therapy and clinical trials. Chandalia M; Jialal I Curr Opin Lipidol; 2005 Dec; 16(6):708-10. PubMed ID: 16276251 [No Abstract] [Full Text] [Related]
17. Is there a problem with ezetimibe or just ENHANCEd hype? Whayne TF Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445 [No Abstract] [Full Text] [Related]
18. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance. Charles Z; Pugh E; Barnett D Heart; 2008 May; 94(5):642-3. PubMed ID: 18411354 [No Abstract] [Full Text] [Related]
19. [Clinical efficacy of ezetimibe and combined use with statins]. Pascual Izuel JM; Rodilla Sala E; Sánchez Juan C Rev Clin Esp; 2005 Oct; 205(10):496-8. PubMed ID: 16238961 [TBL] [Abstract][Full Text] [Related]
20. ARBITER 6-HALTS. Does it have the power to settle all matters? Ferrario CM Ther Adv Cardiovasc Dis; 2010 Apr; 4(2):77-81. PubMed ID: 20360390 [No Abstract] [Full Text] [Related] [Next] [New Search]